This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

Additional data from post-hoc analyses

The following data is from post-hoc analyses and therefore when interpreting this data, the limitations of post-hoc analyses should be taken into consideration.

UC Patients can benefit from a rapid and significant reduction in symptoms with XELJANZ, seen as early as 3 days​​​​​​​1

For patients with moderately to severely active ulcerative colitis, onset of action is an important consideration when choosing appropriate therapy to provide timely symptomatic relief1

​​​​​​​Based on post-hoc analyses of daily patient diary data from the OCTAVE induction studies:

Significant reductions in rectal bleeding vs placebo were seen as early as 3 days:

Mean change from baseline rectal bleeding subscore of -0.30 vs -0.14; p<0.01

Significant reductions in stool frequency vs placebo were seen as early as 3 days:

Mean change from baseline stool frequency subscore of -0.27 vs -0.11; p<0.01

*Relates to results from a post-hoc analysis, consideration should be made for multiple testing and inclusion of unadjusted p-values when interpreting data.
Post-hoc analysis of pooled data from Induction 1 and 2 trials. Daily Mayo stool frequency and rectal bleeding subscores were calculated using patient diary data collected daily during the first 15 days of induction therapy. Partial Mayo Score subscore data were first collected at Day 15.

With XELJANZ, rapid reduction in symptoms, seen within 3 days are irrespective of prior TNFi therapy failure status, baseline steroid use, or baseline C-reactive protein level​​​​​​​1

Percentage of patients with reduction from baseline Mayo rectal bleeding subscore >1 excludes patients with baseline Mayo rectal bleeding subscore = 0
§Percentage of patients with reduction from baseline Mayo stool frequency subscore of >1 excludes patients with baseline Mayo stool frequency subscore = 0

Explore more

Dosing in UC

Visit page


Prescribing Information:

XELJANZ (tofacitinib citrate) Prescribing Information -  5mg and 10mg film-coated tablets

References:
​​​​​​​
  1. Hanauer S et al. Clin Gastroenterol Hepatol 2019;17:139-47
  2. Hanauer S et al. Clin Gastroenterol Hepatol 2019;17(Suppl):139-47
PP-XEL-GBR-2318. June 2021

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

Clinical Efficacy UC

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No